$THC
TENET HEALTHCARE CORP Stock $thc

$thc Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-Q Financial Statement

#000110465913034780 Filed on April 30, 2013

Income Statement

Concept	2013 Q1	2012 Q1
Revenue	$2.387B	$2.302B
YoY Change	3.69%	2.31%
Cost Of Revenue	$384.0M	$399.0M
YoY Change	-3.76%	0.76%
Gross Profit	$2.003B	$1.903B
YoY Change	5.25%	2.64%
Gross Profit Margin	83.91%	82.67%
Selling, General & Admin	$1.203B	$1.099B
YoY Change	9.46%	8.06%
% of Gross Profit	60.06%	57.75%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$114.0M	$100.0M
YoY Change	14.0%	-0.99%
% of Gross Profit	5.69%	5.25%
Operating Expenses	$1.843B	$1.693B
YoY Change	8.86%	7.08%
Operating Profit	$146.0M	$205.0M
YoY Change	-28.78%	-19.29%
Interest Expense	$103.0M	$98.00M
YoY Change	5.1%	-16.95%
% of Operating Profit	70.55%	47.8%
Other Income/Expense, Net
YoY Change
Pretax Income	-$134.0M	$108.0M
YoY Change	-224.07%	-21.17%
Income Tax	-$53.00M	$42.00M
% Of Pretax Income		38.89%
Net Earnings	-$83.00M	$67.00M
YoY Change	-223.88%	-18.29%
Net Earnings / Revenue	-3.48%	2.91%
Basic Earnings Per Share	-$0.85	$0.56
Diluted Earnings Per Share	-$0.85	$0.53
COMMON SHARES
Basic Shares Outstanding	104.1M shares	102.8M shares
Diluted Shares Outstanding	104.1M shares	121.2M shares

Balance Sheet

Concept	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$95.00M	$104.0M
YoY Change	-8.65%	-61.48%
Cash & Equivalents	$95.00M	$104.0M
Short-Term Investments
Other Short-Term Assets	$455.0M	$386.0M
YoY Change	17.88%	-45.48%
Inventory	$152.0M	$157.0M
Prepaid Expenses
Receivables	$1.383B	$1.417B
Other Receivables	$4.000M	$5.000M
Total Short-Term Assets	$2.443B	$2.482B
YoY Change	-1.57%	3.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.296B	$4.324B
YoY Change	-0.65%	1.45%
Goodwill	$948.0M	$738.0M
YoY Change	28.46%
Intangibles
YoY Change
Long-Term Investments	$163.0M	$153.0M
YoY Change	6.54%	-5.56%
Other Assets	$479.0M	$342.0M
YoY Change	40.06%	-41.94%
Total Long-Term Assets	$6.472B	$6.063B
YoY Change	6.75%	-1.11%
TOTAL ASSETS
Total Short-Term Assets	$2.443B	$2.482B
Total Long-Term Assets	$6.472B	$6.063B
Total Assets	$8.915B	$8.545B
YoY Change	4.33%	0.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$625.0M	$640.0M
YoY Change	-2.34%	0.31%
Accrued Expenses	$472.0M	$497.0M
YoY Change	-5.03%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$52.00M	$288.0M
YoY Change	-81.94%	323.53%
Total Short-Term Liabilities	$1.549B	$1.840B
YoY Change	-15.82%	11.04%
LONG-TERM LIABILITIES
Long-Term Debt	$5.375B	$4.295B
YoY Change	25.15%	7.0%
Other Long-Term Liabilities	$611.0M	$526.0M
YoY Change	16.16%	-44.34%
Total Long-Term Liabilities	$611.0M	$526.0M
YoY Change	16.16%	-89.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.549B	$1.840B
Total Long-Term Liabilities	$611.0M	$526.0M
Total Liabilities	$7.833B	$6.998B
YoY Change	11.93%	4.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.376B	-$1.376B
YoY Change	0.0%
Common Stock	$7.000M	$27.00M
YoY Change	-74.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.078B	$1.879B
YoY Change	10.59%
Treasury Stock Shares	40.17M shares	138.1M shares
Shareholders Equity	$969.0M	$1.460B
YoY Change
Total Liabilities & Shareholders Equity	$8.915B	$8.545B
YoY Change	4.33%	0.25%

Cashflow Statement

Concept	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$83.00M	$67.00M
YoY Change	-223.88%	-18.29%
Depreciation, Depletion And Amortization	$114.0M	$100.0M
YoY Change	14.0%	-0.99%
Cash From Operating Activities	-$32.00M	-$42.00M
YoY Change	-23.81%	2000.0%
INVESTING ACTIVITIES
Capital Expenditures	$133.0M	-$136.0M
YoY Change	-197.79%	17.24%
Acquisitions	$5.000M
YoY Change
Other Investing Activities	-$2.000M	-$2.000M
YoY Change	0.0%	-84.62%
Cash From Investing Activities	-$104.0M	-$136.0M
YoY Change	-23.53%	5.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$100.0M	$26.00M
YoY Change	284.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$133.0M	$169.0M
YoY Change	-178.7%	-2514.29%
NET CHANGE
Cash From Operating Activities	-$32.00M	-$42.00M
Cash From Investing Activities	-$104.0M	-$136.0M
Cash From Financing Activities	-$133.0M	$169.0M
Net Change In Cash	-$269.0M	-$9.000M
YoY Change	2888.89%	-93.48%
FREE CASH FLOW
Cash From Operating Activities	-$32.00M	-$42.00M
Capital Expenditures	$133.0M	-$136.0M
Free Cash Flow	-$165.0M	$94.00M
YoY Change	-275.53%	-17.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	364000000	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	152000000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	153000000	USD
CY2013Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	4000000	USD
CY2012Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7000000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	354000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	354000000	USD
CY2013Q1	us-gaap	Other Assets Current OtherAssetsCurrent	455000000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	458000000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	2443000000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	2681000000	USD
CY2013Q1	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	163000000	USD
CY2012Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	162000000	USD
CY2013Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	395000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	342000000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4296000000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4293000000	USD
CY2013Q1	us-gaap	Goodwill Goodwill	948000000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	916000000	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	670000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	650000000	USD
CY2013Q1	us-gaap	Assets Assets	8915000000	USD
CY2012Q4	us-gaap	Assets Assets	9044000000	USD
CY2013Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	52000000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	94000000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	625000000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	722000000	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	373000000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	415000000	USD
CY2013Q1	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	49000000	USD
CY2012Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	64000000	USD
CY2013Q1	us-gaap	Interest Payable Current InterestPayableCurrent	99000000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	125000000	USD
CY2013Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	351000000	USD
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	343000000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1549000000	USD
CY2013Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5375000000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5158000000	USD
CY2013Q1	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	298000000	USD
CY2012Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	292000000	USD
CY2013Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	198000000	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	611000000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	597000000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	7833000000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	7810000000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4484000000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4471000000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-68000000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-68000000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1376000000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1288000000	USD
CY2013Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2078000000	USD
CY2012Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	189000000	USD
CY2013Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2387000000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1979000000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	969000000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1143000000	USD
CY2013Q1	us-gaap	Minority Interest MinorityInterest	77000000	USD
CY2012Q4	us-gaap	Minority Interest MinorityInterest	75000000	USD
CY2013Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1046000000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1218000000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8915000000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9044000000	USD
CY2013Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	407000000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	401000000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3494000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	426000000	USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	143597960	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142363915	shares
CY2013Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	40172225	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	37730431	shares
CY2013Q1	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	2594000000	USD
CY2012Q1	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	2491000000	USD
CY2013Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	207000000	USD
CY2012Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2302000000	USD
CY2013Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1161000000	USD
CY2012Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1062000000	USD
CY2013Q1	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	384000000	USD
CY2012Q1	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	399000000	USD
CY2013Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	568000000	USD
CY2012Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	531000000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114000000	USD
CY2012Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000000	USD
CY2013Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2012Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-2000000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	146000000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	205000000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	103000000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	98000000	USD
CY2013Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2012Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	1000000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-134000000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	108000000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53000000	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42000000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-81000000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	66000000	USD
CY2013Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-3000000	USD
CY2012Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	2000000	USD
CY2012Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-88000000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	58000000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-86000000	USD
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.53
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104103000	shares
CY2012Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102843000	shares
CY2013Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-1000000	USD
CY2012Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	1000000	USD
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2000000	USD
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	1000000	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-83000000	USD
CY2012Q1	us-gaap	Profit Loss ProfitLoss	67000000	USD
CY2013Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	57000000	USD
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-2000000	USD
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1000000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.55
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.01
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2013Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.83
CY2012Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.52
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.01
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104103000	shares
CY2012Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121218000	shares
CY2013Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	0	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	-3000000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	0	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	3000000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-83000000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	70000000	USD
CY2012Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	38000000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8000000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9000000	USD
CY2013Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	5000000	USD
CY2012Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	3000000	USD
CY2013Q1	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	3000000	USD
CY2012Q1	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	3000000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104000000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-136000000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	200000000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	455000000	USD
CY2013Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	220000000	USD
CY2012Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	658000000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	899000000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	4000000	USD
CY2013Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	100000000	USD
CY2012Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	26000000	USD
CY2013Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2012Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	6000000	USD
CY2013Q1	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	6000000	USD
CY2012Q1	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	3000000	USD
CY2013Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	2000000	USD
CY2012Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	3000000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-133000000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169000000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-269000000	USD
CY2013Q1	us-gaap	Interest Paid Net InterestPaidNet	-125000000	USD
CY2012Q1	us-gaap	Interest Paid Net InterestPaidNet	-102000000	USD
CY2013Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000000	USD
CY2012Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-2000000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113000000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104000000	USD
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	TENET HEALTHCARE CORP
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000070318
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103501059	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	3000000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	61000000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	5000000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-88000000	USD
CY2012Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000000	USD
CY2013Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	36000000	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2013Q1	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"> </p> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Net Operating Revenues</font></i></b> <b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic" size="2">Before Provision for Doubtful Accounts</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our</font><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic" size="2">Compact with Uninsured Patients</font></i> <font style="FONT-SIZE: 10pt" size="2">(“Compact”)</font><font style="FONT-SIZE: 10pt" size="2">.</font></p> <p style="MARGIN: 0in 0in 0pt"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The table below shows the sources of net operating revenues before provision for doubtful accounts:</font></p> <p style="MARGIN: 0in 0in 0pt"> </p> <table style="WIDTH: 995px; BORDER-COLLAPSE: collapse; HEIGHT: 212px" cellspacing="0" cellpadding="0" width="995" border="0"> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 33.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="33%" colspan="5"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Three Months Ended<br />  March 31,</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.52%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2013</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.52%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">General Hospitals:</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.52%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="15%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.52%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="15%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Medicare</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.22%; PADDING-TOP: 0in" valign="bottom" width="14%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">540</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.22%; PADDING-TOP: 0in" valign="bottom" width="14%"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">629</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Medicaid</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">188</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">177</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Managed care</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,361</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,326</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Indemnity, self-pay and other</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">260</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">241</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Acute care hospitals — other revenue</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">28</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">24</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other:</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15.52%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"> </p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%"> <p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other operations</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.52%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">217</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.52%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%" colspan="2"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">94</font></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.76%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Net operating revenues before provision for doubtful accounts</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.22%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="14%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,594</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></b></p></td> <td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.22%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="14%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,491</font></b></p></td> <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"> <p style="MARGIN: 0in 0in 0pt"> </p></td></tr></table></div>
CY2013Q1	thc	Number Of Hospitals Operated By Subsidiaries NumberOfHospitalsOperatedBySubsidiaries	49	item
CY2013Q1	thc	Number Of Licensed Beds In Hospitals Operated By Subsidiaries NumberOfLicensedBedsInHospitalsOperatedBySubsidiaries	13180	item
CY2013Q1	thc	Number Of Free Standing And Provider Based Out Patient Centers Operated By Subsidiaries NumberOfFreeStandingAndProviderBasedOutPatientCentersOperatedBySubsidiaries	122	item
CY2012	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	98000000	USD
CY2013Q1	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	39000000	USD
CY2013Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	31000000	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1117000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1076000000	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	86000000	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	94000000	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	78000000	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	71000000	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	57000000	USD
CY2013Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	3000000	USD
CY2012Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	56000000	USD
CY2012Q4	us-gaap	Restructuring Reserve RestructuringReserve	12000000	USD
CY2013Q1	us-gaap	Restructuring Reserve RestructuringReserve	14000000	USD
CY2011Q4	us-gaap	Restructuring Reserve RestructuringReserve	11000000	USD
CY2012Q1	us-gaap	Restructuring Reserve RestructuringReserve	10000000	USD
CY2013Q1	us-gaap	Restructuring Charges RestructuringCharges	10000000	USD
CY2012Q1	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2013Q1	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	-6000000	USD
CY2012Q1	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	1000000	USD
CY2013Q1	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-2000000	USD
CY2012Q1	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	0	USD
CY2013Q1	thc	Cash Payments To Be Applied Against Accruals Due Within One Year CashPaymentsToBeAppliedAgainstAccrualsDueWithinOneYear	9000000	USD
CY2013Q1	thc	Cash Payments To Be Applied Against Accruals Due Thereafter CashPaymentsToBeAppliedAgainstAccrualsDueThereafter	5000000	USD
CY2012Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	119000000	USD
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	116000000	USD
CY2012Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	5252000000	USD
CY2013Q1	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	5427000000	USD
CY2013Q1	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	63000000	USD
CY2013Q1	us-gaap	Capital Lease Obligations CapitalLeaseObligations	140000000	USD
CY2013Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3835818	shares
CY2013Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2013Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	31.53
CY2013Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3247003	shares
CY2013Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	31.60
CY2013Q1	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	26000000	USD
CY2012Q1	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	28000000	USD
CY2012Q2	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Retired PreferredStockSevenPercentMandatoryConvertibleSharesRetired	298700	shares
CY2013Q1	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2012Q2	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	289000000	USD
CY2012Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	46300	shares
CY2012Q4	us-gaap	Stock Repurchase Program Authorized Amount StockRepurchaseProgramAuthorizedAmount	500000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	200000000	USD
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	5860730	shares
CY2012Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3406000	shares
CY2012Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	400000000	USD
CY2012Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	29.36
CY2013Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	531000	shares
CY2013Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	914000	shares
CY2013Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1010000	shares
CY2013Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	37.13
CY2013Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	39.30
CY2013Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	43.95
CY2013Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	380000000	USD
CY2013Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	344000000	USD
CY2013Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	300000000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1492000000	USD
CY2013Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	6000000	USD
CY2012Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	3000000	USD
CY2013Q1	us-gaap	Minority Interest Increase From Stock Issuance MinorityInterestIncreaseFromStockIssuance	0	USD
CY2012Q1	us-gaap	Minority Interest Increase From Stock Issuance MinorityInterestIncreaseFromStockIssuance	2000000	USD
CY2013Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	100000000	USD
CY2012Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	26000000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14000000	USD
CY2012Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000000	USD
CY2012Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10000000	USD
CY2013Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	9000000	USD
CY2011Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	66000000	USD
CY2012Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	58000000	USD
CY2013Q1	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	1000000	USD
CY2012Q1	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	10000000	USD
CY2013Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	32000000	USD
CY2013Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	8000000	USD
CY2013Q1	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	8000000	USD
CY2013Q1	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2012Q1	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	6000000	USD
CY2013Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2012Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	18375000	shares
CY2013Q1	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	0.00
CY2012Q1	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.03
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-86000000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	63000000	USD
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1472000	shares
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3829000	shares
CY2013Q1	thc	Preferred Stock And Other Securities Held By Captive Insurance Subsidiaries PreferredStockAndOtherSecuritiesHeldByCaptiveInsuranceSubsidiaries	1000000	USD
CY2013Q1	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.067	pure
CY2012Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.082	pure
CY2013Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	4000000	USD
CY2013Q1	thc	Number Of Hospitals Owned By Subsidiaries NumberOfHospitalsOwnedBySubsidiaries	49	item
CY2013Q1	thc	Number Of Licensed Beds In Hospitals Operated By The Subsidiaries NumberOfLicensedBedsInHospitalsOperatedByTheSubsidiaries	13180	item
CY2013Q1	thc	Number Of Free Standing And Provider Based Diagnostic Imaging Centers And Ambulatory Surgery Centers Operated By Subsidiaries Excluding Classified In Discontinued Operations NumberOfFreeStandingAndProviderBasedDiagnosticImagingCentersAndAmbulatorySurgeryCentersOperatedBySubsidiariesExcludingClassifiedInDiscontinuedOperations	122	item
CY2013Q1	thc	Number Of Hospitals To Which Segment Of The Entity Provides Revenue Cycle Services NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices	600	item
CY2013Q1	thc	Capital Expenditure CapitalExpenditure	133000000	USD
CY2013Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	284000000	USD
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	34.12
CY2012Q1	thc	Capital Expenditure CapitalExpenditure	136000000	USD
CY2013Q1	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-92000000	USD
CY2012Q1	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-90000000	USD
CY2013Q1	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	274000000	USD
CY2012Q1	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	310000000	USD
CY2013Q1	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	-134000000	USD
CY2012Q1	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	108000000	USD
CY2013Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-2000000	USD
CY2012Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-2000000	USD
CY2013Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-177000000	USD
CY2012Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	850000000	USD
CY2013Q1	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	-29000000	USD
CY2013Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5000000	USD
CY2012Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3000000	USD
CY2012Q1	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	2000000	USD
CY2013Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	15000000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	0	USD
CY2012Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3000000	USD
CY2013Q1	thc	Minimum Number Of Hospitals To Which Business Process Solution Is Provided By Subsidiaries MinimumNumberOfHospitalsToWhichBusinessProcessSolutionIsProvidedBySubsidiaries	600	item
CY2013Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000000	USD
CY2012Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000000	USD

Files In Submission

Name	View Source	Status
0001104659-13-034780-index-headers.html	Edgar Link	pending
0001104659-13-034780-index.html	Edgar Link	pending
0001104659-13-034780.txt	Edgar Link	pending
0001104659-13-034780-xbrl.zip	Edgar Link	pending
a13-8668_110q.htm	Edgar Link	pending
a13-8668_1ex31da.htm	Edgar Link	pending
a13-8668_1ex31db.htm	Edgar Link	pending
a13-8668_1ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thc-20130331.xml	Edgar Link	completed
thc-20130331.xsd	Edgar Link	pending
thc-20130331_cal.xml	Edgar Link	unprocessable
thc-20130331_def.xml	Edgar Link	unprocessable
thc-20130331_lab.xml	Edgar Link	unprocessable
thc-20130331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THC
TENET HEALTHCARE CORP Stock $thc

2013 Q1 Form 10-Q Financial Statement

#000110465913034780 Filed on April 30, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC TENET HEALTHCARE CORP Stock $thc

2013 Q1 Form 10-Q Financial Statement

#000110465913034780 Filed on April 30, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC
TENET HEALTHCARE CORP Stock $thc